|
|
Blood, 1 July 2007, Vol. 110, No. 1, pp. 171-179.
Prepublished online as a Blood First Edition Paper on March 28, 2007; DOI 10.1182/blood-2007-02-071589.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway
Zhao Chen1,2,
Olaia Naveiras3,4,
Alessandra Balduini5,
Akiko Mammoto6,7,
Mary Anne Conti8,
Robert S. Adelstein8,
Donald Ingber6,7,
George Q. Daley3,4, and
Ramesh A. Shivdasani1,2
1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
2 Department of Medicine, Harvard Medical School, Boston, MA;
3 Division of Hematology and Oncology, Children's Hospital, Boston, MA;
4 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA;
5 Department of Biochemistry, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;
6 Vascular Biology Program, Children's Hospital, Boston, MA;
7 Departments of Pathology and Surgery, Harvard Medical School, Boston, MA; and
8 Laboratory of Molecular Cardiology, National Heart, Lung and Blood Institute, Bethesda, MD
The gene implicated in the May-Hegglin anomaly and related macrothrombocytopenias, MYH9, encodes myosin-IIA, a protein that enables morphogenesis in diverse cell types. Defective myosin-IIA complexes are presumed to perturb megakaryocyte (MK) differentiation or generation of proplatelets. We observed that Myh9/ mouse embryonic stem (ES) cells differentiate into MKs that are fully capable of proplatelet formation (PPF). In contrast, elevation of myosin-IIA activity, by exogenous expression or by mimicking constitutive phosphorylation of its regulatory myosin light chain (MLC), significantly attenuates PPF. This effect occurs only in the presence of myosin-IIA and implies that myosin-IIA influences thrombopoiesis negatively. MLC phosphorylation in MKs is regulated by Rho-associated kinase (ROCK), and consistent with our model, ROCK inhibition enhances PPF. Conversely, expression of AV14, a constitutive form of the ROCK activator Rho, blocks PPF, and this effect is rescued by simultaneous expression of a dominant inhibitory MLC form. Hematopoietic transplantation studies in mice confirm that interference with the putative RhoROCKmyosin-IIA pathway selectively decreases the number of circulating platelets. Our studies unveil a key regulatory pathway for platelet biogenesis and hint at Sdf-1/CXCL12 as one possible extracellular mediator. The unexpected mechanism for Myh9-associated thrombocytopenia may lead to new molecular approaches to manipulate thrombopoiesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
ROCK and Rho(ll) in bone marrow
- Alan T. Nurden
Blood 2007 110: 5-6.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. E. Geddis
The regulation of proplatelet production
Haematologica,
June 1, 2009;
94(6):
756 - 759.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Eckly, C. Strassel, M. Freund, J.-P. Cazenave, F. Lanza, C. Gachet, and C. Leon
Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation
Blood,
April 2, 2009;
113(14):
3182 - 3189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. Nurden
Thrombus stability on the vessel wall
Blood,
July 1, 2008;
112(1):
4 - 5.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kunishima, M. Hamaguchi, and H. Saito
Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders
Blood,
March 15, 2008;
111(6):
3015 - 3023.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Morin, P. W. Oakes, Y.-M. Hyun, D. Lee, Y. E. Chin, M. R. King, T. A. Springer, M. Shimaoka, J. X. Tang, J. S. Reichner, et al.
Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration
J. Exp. Med.,
January 21, 2008;
205(1):
195 - 205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. Nurden and P. Nurden
Inherited thrombocytopenias
Haematologica,
September 1, 2007;
92(9):
1158 - 1164.
[Full Text]
[PDF]
|
 |
|
|
|